Bisphosphonate News and Research

RSS

Bisphosphonate is a drug or substance used to treat hypercalcemia (abnormally high blood calcium) and bone pain caused by some types of cancer. Forms of bisphosphonates are also used to treat osteoporosis and for bone imaging. Bisphosphonates inhibit a type of bone cell that breaks down bone. Also called diphosphonate.

Osteoporosis study: Protelos have significant bone-forming activity than bisphosphonates

Protelos has significantly greater bone-forming activity than the commonly prescribed bisphosphonate, alendronate, according to results of the largest-ever biopsy study in post-menopausal women presented today at the European Congress on Osteoporosis and Osteoarthritis in Valencia.

25 Mar 2011

Prolia associated with greater adherence than alendronate in postmenopausal women with osteoporosis

Amgen today announced new data that showed postmenopausal women with osteoporosis had significantly greater adherence, compliance, and persistence during Prolia® (denosumab) treatment than during alendronate treatment, an oral bisphosphonate commonly used to treat osteoporosis.

24 Mar 2011

$HIV infection and increased fracture risk: Study$

HIV infection and increased fracture risk: Study

According to a latest study, adults between ages 25 and 54 infected with HIV, are at increased risk for bone fractures compared to the general population. Until now it was known that low bone mineral density was common in people with HIV, but no concrete proof existed.

14 Mar 2011

CWRU: Postmenopausal women need more dental checkups

Postmenopausal women have a new health message to hear. Two annual dental checkups aren't enough. Older women need more, according to research findings from the Case Western Reserve University School of Dental Medicine and the Cleveland Clinic.

11 Mar 2011

Warner Chilcott fourth quarter revenue increases 1% to $694.4 million

Warner Chilcott plc today announced its results for the quarter and year ended December 31, 2010. As discussed more fully below, our financial position and results of operations in the quarter ended December 31, 2010 as compared to the prior year quarter were significantly impacted by several important transactions in 2009 and 2010.

25 Feb 2011

$Prolonged use of osteoporosis drugs may increase risk of unusual fractures in women$

Prolonged use of osteoporosis drugs may increase risk of unusual fractures in women

Women who take commonly prescribed drugs for osteoporosis known as bisphosphonates for five years or more may be at higher risk of certain kinds of fractures of their thigh bone, a new study has found.

23 Feb 2011

Positive interim data from cabozantinib Phase 2 metastatic castration-resistant prostate cancer trial

Exelixis, Inc. today reported updated interim data from the cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial.

18 Feb 2011

State court jury rules in favor of Merck in FOSAMAX trial

Merck & Co., Inc. today said a state court jury in New Jersey found in its favor in the Rosenberg v. Merck case, rejecting the claims of a woman who blamed her dental and jaw related problems on her FOSAMAX use.

15 Feb 2011

Oral bisphosphonates outweigh the risk associated with jaw disease

A commonly prescribed osteoporosis drug is associated with a slightly elevated risk of developing the rare, but serious condition, osteonecrosis of the jaw; nonetheless the risk remains extremely low. These findings are published online in the Journal of Dental Research, the official journal of the International and American Associations for Dental Research.

14 Feb 2011

JDR releases research report on Osteonecrosis of the jaw

Osteonecrosis of the jaw is a debilitating bone condition that affects the jaws and occurs as a result of reduced local blood supply to the bone. The literature in this area has been severely limited since most investigations cannot evaluate sufficient numbers of afflicted individuals to accurately determine the incidence of the disease and associated risk factors.

14 Feb 2011

Rare new disease identified – calcium accumulates in blood vessels

A new rare disease has been identified. Louise Benge’s started having difficulty in walking when she was 25. She developed hardening and pain over her calves and hands. She worsened over the next 20 years. Her family physician in Mount Vernon, Ky., was at a loss, as were a vascular specialist, a hand specialist and a kidney specialist. Her two sisters and two brothers had the problem too, but no doctor could understand why.

3 Feb 2011

Longer life with osteoporosis therapy: Study

In a new breakthrough, Australian scientists have identified the “remarkable” life-extending properties of an osteoporosis treatment. The research is published in the Journal of Endocrinology and Metabolism on Thursday.

3 Feb 2011

Bisphosphonates help people with osteoporosis gain extra 5 years of life

Australian clinical researchers have noted an extraordinary and unexpected benefit of osteoporosis treatment - that people taking bisphosphonates are not only surviving well, better than people without osteoporosis, they appear to be gaining an extra five years of life. These findings are published in the Journal of Clinical Endocrinology and Metabolism, now online.

3 Feb 2011

Quebec provides access to new treatment for women with postmenopausal osteoporosis

Today Quebec is providing access to a therapy in a new class of osteoporosis treatments. With Quebec being the first province to list Prolia on public and private drug plans, Canadians living with osteoporosis in the province of Quebec now have access to increased treatment options.

2 Feb 2011

Enobia Pharma completes ENB-0040 Phase II study in juveniles with hypophosphatasia

Enobia Pharma, today announced that it has successfully completed a Phase II study of ENB-0040, a bone targeted enzyme replacement therapy being investigated in juveniles with hypophosphatasia, a serious, rare metabolic bone disorder.

10 Jan 2011

EffRx submits EX101 NDA for osteoporosis treatment to FDA

EffRx Pharmaceuticals SA, a Lausanne, Switzerland based drug delivery company announces the NDA submission of the company's lead project to the US Food and Drug Administration.

10 Jan 2011

Presence of circulating tumor cells in early-stage breast cancer doubles risk of relapse and death

The presence of one to four circulating tumor cells (CTCs) in the blood of early-stage breast cancer patients almost doubled patient's risk of cancer relapse and death, and five or more CTCs increased recurrence by 400 percent and death by 300 percent, according to Phase III results of the SUCCESS trial. These cells were found in patients after surgery but before chemotherapy treatment.

13 Dec 2010

Zometa improves OS, PFS in newly diagnosed multiple myeloma patients: Phase III study

A newly published study in the Lancet suggested that a first-line treatment regimen including Zometa (zoledronic acid) significantly improved overall survival and progression-free survival in newly diagnosed multiple myeloma patients compared with a regimen that included oral clodronate. The impact on survival was independent of the effect of Zometa on bone complications (also known as skeletal-related events or SREs).

4 Dec 2010

$ESCEO and IOF publish position paper on link between upper thigh bone fractures and bisphosphonate use$

ESCEO and IOF publish position paper on link between upper thigh bone fractures and bisphosphonate use

Leading experts from the European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF) have published a timely position paper on the association between subtrochanteric femoral (upper thigh bone) fractures and long-term treatment with bisphosphonates.

25 Nov 2010

Merck wins third FOSAMAX bellwether trial

Merck & Co., Inc. today said a federal court jury in New York found in its favor in the Graves v. Merck case, rejecting the claims of a Florida woman who blamed her dental and jaw related problems on her FOSAMAX use. With today's verdict, Merck has won three of the first four bellwether cases in the FOSAMAX litigation.

20 Nov 2010

Bisphosphonate News and Research

Further Reading

Osteoporosis study: Protelos have significant bone-forming activity than bisphosphonates

Prolia associated with greater adherence than alendronate in postmenopausal women with osteoporosis

HIV infection and increased fracture risk: Study

CWRU: Postmenopausal women need more dental checkups

Warner Chilcott fourth quarter revenue increases 1% to $694.4 million

Prolonged use of osteoporosis drugs may increase risk of unusual fractures in women

Positive interim data from cabozantinib Phase 2 metastatic castration-resistant prostate cancer trial

State court jury rules in favor of Merck in FOSAMAX trial

Oral bisphosphonates outweigh the risk associated with jaw disease

JDR releases research report on Osteonecrosis of the jaw

Rare new disease identified – calcium accumulates in blood vessels

Longer life with osteoporosis therapy: Study

Bisphosphonates help people with osteoporosis gain extra 5 years of life

Quebec provides access to new treatment for women with postmenopausal osteoporosis

Enobia Pharma completes ENB-0040 Phase II study in juveniles with hypophosphatasia

EffRx submits EX101 NDA for osteoporosis treatment to FDA

Presence of circulating tumor cells in early-stage breast cancer doubles risk of relapse and death

Zometa improves OS, PFS in newly diagnosed multiple myeloma patients: Phase III study

ESCEO and IOF publish position paper on link between upper thigh bone fractures and bisphosphonate use

Merck wins third FOSAMAX bellwether trial

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News